{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:19Z","timestamp":1772166559078,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001427"],"award-info":[{"award-number":["UL1TR001427"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AI153544"],"award-info":[{"award-number":["K01AI153544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We present 16s rRNA gene sequencing (V1-V2 region) and sample data from a pilot observational cohort study to describe the gut microbiota dynamics of subjects with latent tuberculosis infection (LTBI)\u00a0treated with daily 600 mg rifampicin for four months (4R)\u00a0or a weekly dose of 900 mg combination of rifapentine and isoniazid for three months (3HP). Our objectives were to (1) document changes to the gut microbiota immediately following exposure to the rifamycins and (2) document recovery to baseline two months after treatment completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data description<\/jats:title>\n                    <jats:p>We enrolled six subjects with subjects with LTBI and prospectively followed them for 5\u20136 months. Each subject provided stool samples before, during, and two months after treatment. Six healthy controls were sampled in parallel with the patients with LTBIs. We report amplicon sequence variants (ASVs) and taxonomic assignments for 60 stool samples. Additionally, we provide access to the raw amplicon sequences, and subject responses to questionnaires about their diet, medication, and lifestyle changes over the study follow-up period. Furthermore, we provide the concentration of the parent and partially active rifamycin metabolite concentrations measured validated LC-MS-MS assays of phosphate buffer washes of the stool samples collected from the LTBI participants. This comprehensive dataset is a valuable resource for future systematic reviews and meta-analyses of the impact of LTBI therapy on the gut microbiota.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-023-06370-7","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T07:02:24Z","timestamp":1686553344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["16S rRNA gene sequencing of stool samples collected from patients with latent tuberculosis infection before, during, and two months after treatment with 3HP or 4R"],"prefix":"10.1186","volume":"16","author":[{"given":"Marie Nancy","family":"S\u00e9raphin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bellot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"6370_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrmicro.2016.142","volume":"15","author":"KF Budden","year":"2017","unstructured":"Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut\u2013lung axis. Nat Rev Microbiol. 2017;15:55\u201363.","journal-title":"Nat Rev Microbiol"},{"key":"6370_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3389\/fimmu.2018.00709","volume":"9","author":"N Gupta","year":"2018","unstructured":"Gupta N, Kumar R, Agrawal B. New Players in immunity to tuberculosis: the host Microbiome, Lung Epithelium, and Innate Immune cells. Front Immunol. 2018;9:709.","journal-title":"Front Immunol"},{"key":"6370_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00018-019-03370-4","volume":"77","author":"OA Eribo","year":"2020","unstructured":"Eribo OA, du Plessis N, Ozturk M, Guler R, Walzl G, Chegou NN. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell Mol Life Sci. 2020;77:1497\u2013509.","journal-title":"Cell Mol Life Sci"},{"key":"6370_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.molmed.2016.04.003","volume":"22","author":"S Becattini","year":"2016","unstructured":"Becattini S, Taur Y, Pamer EG. Antibiotic-Induced changes in the intestinal microbiota and disease. Trends Mol Med. 2016;22:458\u201378.","journal-title":"Trends Mol Med"},{"key":"6370_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","volume":"22","author":"MM Macaraig","year":"2018","unstructured":"Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018;22:1344\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"6370_CR6","doi-asserted-by":"publisher","first-page":"a017830","DOI":"10.1101\/cshperspect.a017830","volume":"5","author":"L Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz L, Stagg HR, Abubakar I. Diagnosis and management of latent tuberculosis infection. Cold Spring Harb Perspect Med. 2015;5:a017830.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6370_CR7","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1128\/AEM.65.11.4715-4724.1999","volume":"65","author":"DN Miller","year":"1999","unstructured":"Miller DN, Bryant JE, Madsen EL, Ghiorse WC. Evaluation and optimization of DNA extraction and purification procedures for soil and sediment samples. Appl Environ Microbiol. 1999;65:4715\u201324.","journal-title":"Appl Environ Microbiol"},{"key":"6370_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10552-021-01420-6","volume":"32","author":"L Yaghjyan","year":"2021","unstructured":"Yaghjyan L, Mai V, Wang X, Ukhanova M, Tagliamonte M, Martinez YC, et al. Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women. Cancer Causes Control. 2021;32:681\u201392.","journal-title":"Cancer Causes Control"},{"key":"6370_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581\u20133.","journal-title":"Nat Methods"},{"key":"6370_CR10","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1128\/AEM.00062-07","volume":"73","author":"Q Wang","year":"2007","unstructured":"Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261\u20137.","journal-title":"Appl Environ Microbiol"},{"key":"6370_CR11","doi-asserted-by":"crossref","unstructured":"Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009;37 Database issue:D141\u20135.","DOI":"10.1093\/nar\/gkn879"},{"key":"6370_CR12","doi-asserted-by":"crossref","unstructured":"S\u00e9raphin Marie Nancy. Gut microbiome dynamics associated with rifamycin therapy for latent tuberculosis infection - Raw Sequences. NCBI Sequence Archive. 2021. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA772261. Accessed 24 Oct 2022.","DOI":"10.21203\/rs.3.rs-2313802\/v1"},{"key":"6370_CR13","doi-asserted-by":"publisher","unstructured":"S\u00e9raphin Marie Nancy. Gut microbiome amplicon sequence variants (ASVs) and sample data from patients with tuberculosis infection before, during, and after treatment with rifamycins. FigShare. 2022. https:\/\/doi.org\/10.6084\/m9.figshare.21381930.","DOI":"10.6084\/m9.figshare.21381930"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06370-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T07:06:30Z","timestamp":1686553590000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06370-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6370"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06370-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2199576\/v1","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research described involved human participants, human material, and human data. All methods were performed in accordance with the Declaration of Helsinki. The study protocol was reviewed and approved by the University of Florida (IRB201801385) and the Florida Department of Health Institutional Review Boards (2018-057). Each study participant provided written inform consent prior to all study activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"100"}}